Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance

International Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 134-140

  Yanase, Kae ^a,b   Sugimoto, Yoshikazu ^a   Andoh, Toshiwo ^b   Tsuruo, Takashi ^a,c  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b SOKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; COMPLEMENTARY DNA; DNA TOPOISOMERASE; DOXORUBICIN; IRINOTECAN; NEOMYCIN; VIRUS VECTOR;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL MUTANT; CELL PROTECTION; CONTROLLED STUDY; CROSS RESISTANCE; DNA DETERMINATION; DNA DRUG COMPLEX; DNA INTEGRATION; DRUG CYTOTOXICITY; ENZYME ACTIVITY; GENE CONSTRUCT; GENETIC TRANSDUCTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOBLAST;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CAMPTOTHECIN; DNA TOPOISOMERASES, TYPE I; DNA, COMPLEMENTARY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCINE; HELA CELLS; HUMANS; MUTATION; NEOMYCIN; NUCLEIC ACID CONFORMATION; POLYMERASE CHAIN REACTION; RETROVIRIDAE; TRANSDUCTION, GENETIC; TRANSFECTION; UTERINE CERVICAL NEOPLASMS;

EID: 0033050831     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990331)81:1<134::AID-IJC22>3.0.CO;2-Y     Document Type: Article

References (19)

1. ANDOH, T., ISHII, K., SUZUKI, Y., IKEGAMI, Y., KUSUNOKI, Y., TAKEMOTO, Y. and OKADA, K., Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc. nat. Acad. Sci. (Wash.), 84, 5565-5569 (1987).
2. ANDOH, T., TAMURA, H., KOHCHI, C., YAMADA, R., IKEDA, T., KOIWAI, O., YASUI, Y., NISHIZAWA, M. and OKADA, K., Mechanism of camptothecin resistance in mammalian cells: mutation in topoisomerase I gene and its implication in enzymatic function. In: T. Andoh, H. Ikeda and M. Oguro (eds.). Molecular biology of DNA topoisomerases and its application to chemotherapy, pp. 229-235, CRC Press, Boca Raton, FL (1993).
3. CHEN, A.Y. and LIU, L. F., DNA topoisomerases: essential enzymes and lethal targets. Ann. Rev. Pharmacol. Toxicol., 34, 191-218 (1994).
4. GOTTESMAN, M.M., HRYCYNA, C., SCHOENLEIN, P.V., GERMANN, U.A. and PASTAN, I., Genetic analysis of the multidrug transporter. Ann. Rev. Genet., 29, 607-649 (1995).
5. HANN, C., EVANS, D.L., FERTALA, J., BENEDETTI, P., BJORNSTI, M.A. and HALL, D.J., Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I. J. biol. Chem., 273, 8425-8433 (1998).
6. HSIANG, Y.-H., HERTZBERG, R., HECHT, S. and LIU, L.F., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. biol. Chem., 260, 14873-14879 (1985).
7. ISHII, K., HASEGAWA, T., FUJISAWA, K. and ANDOH, T., Rapid purification and characterization of DNA topoisomerase I from mouse mammary carcinoma FM3A cells. J. biol. Chem., 258, 12728-12732 (1983).
8. KJELDSEN, E., BONVEN, B.J., ANDOH, T., ISHII, K., OKADA, K., BOLUND, L. and WESTERGAARD, O., Characterization of a camptothecin-resistant human DNA topoisomerase I. J. biol. Chem., 263, 3912-3916 (1988).
9. KNAB, A.M., FERTALA, J. and BJORNSTI, M.A., Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J. biol. Chem., 268, 22322-22330 (1993).
10. KUNIMOTO, T., NITTA, K., TANAKA, T., UEHARA, N., BAHA, H., TAKEUCHI, M., YOKOKURA, T., SAWADA, S., MIYASAKA, T. and MUTAI, M., Anti-tumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47, 5944-5947 (1987).
11. MILLER, A.D. and BUTTIMORE, C., Redesign of retrovirus packaging cell line to avoid recombination leading to helper virus production. Mol. cell. Biol., 6, 2895-2902 (1986).
12. POTMESIL, M. and PINEDO, H. (eds.), Camptothecins: new anticancer agents, CRC Press, Boca Raton, FL (1995).
13. REDINBO, M.R., STEWART, L., KUHN, P., CHAMPOUX, J.J. and HOL, W.G.J., Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science, 279, 1504-1513 (1998).
14. SUGIMOTO, Y., AKSENTIJEVICH, I., GOTTFSMAN, M.M. and PASTAN, I., Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology, 12, 694-698 (1994).
15. SUGIMOTO, Y., AKSENTIJEVICH, I., HRYCYNA, C., PASTAN, I. and GOTTESMAN, M.M., Co-expression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic mRNA in a retrovirus vector allows selective killing of MDR1-transduced cells. Clin. Cancer Res., 1, 447-457 (1995).
16. SUGIMOTO, Y., TSUKAHARA, S., OH-HARA, T., ISOE, T. and TSURUO, T., Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50, 6925-6930 (1990).
17. TAMURA, H., KOHCHI, C., YAMADA, R., IKEDA, T., KOIWAI, O., PATTERSON, E., KEENE, J.D., OKADA, K., KJELDSEN, E., NISHIKAWA, K. and ANDOH, T., Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res., 19, 69-75 (1991).
18. THOMSEN, B., MOLERUP, S., BONVEN, B.J., FRANK, R., BLOCKER, H., NIELSEN, O.F. and WESTERGAARD, O., Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin. EMBO J., 6, 1817-1823 (1987).
19. WANG, J.C., DNA topoisomerases. Ann. Rev. Biochem., 65, 635-692 (1996).